NZ757717B2 - Carbohydrate composition for dialysis - Google Patents
Carbohydrate composition for dialysis Download PDFInfo
- Publication number
- NZ757717B2 NZ757717B2 NZ757717A NZ75771718A NZ757717B2 NZ 757717 B2 NZ757717 B2 NZ 757717B2 NZ 757717 A NZ757717 A NZ 757717A NZ 75771718 A NZ75771718 A NZ 75771718A NZ 757717 B2 NZ757717 B2 NZ 757717B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- maltose
- molecular weight
- glucan
- less
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 185
- 238000000502 dialysis Methods 0.000 title abstract description 56
- 150000001720 carbohydrates Chemical class 0.000 title description 36
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 claims abstract description 148
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 67
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000008103 glucose Substances 0.000 claims abstract description 64
- 150000001413 amino acids Chemical class 0.000 claims abstract description 40
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 23
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims description 25
- 229920001503 Glucan Polymers 0.000 abstract description 104
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 97
- 229960001031 Glucose Drugs 0.000 description 65
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 65
- 229920002177 Icodextrin Polymers 0.000 description 58
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 57
- 238000002360 preparation method Methods 0.000 description 57
- 229920000642 polymer Polymers 0.000 description 54
- 229940016836 icodextrin Drugs 0.000 description 41
- 235000001014 amino acid Nutrition 0.000 description 38
- 229920001282 polysaccharide Polymers 0.000 description 35
- 238000000108 ultra-filtration Methods 0.000 description 27
- 239000007788 liquid Substances 0.000 description 26
- 210000004369 Blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 239000002357 osmotic agent Substances 0.000 description 25
- 239000012530 fluid Substances 0.000 description 23
- 229920002472 Starch Polymers 0.000 description 22
- 235000019698 starch Nutrition 0.000 description 22
- 230000035507 absorption Effects 0.000 description 21
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 21
- 239000008107 starch Substances 0.000 description 21
- 238000010521 absorption reaction Methods 0.000 description 20
- 229960005150 glycerol Drugs 0.000 description 20
- 230000003204 osmotic Effects 0.000 description 20
- 239000000385 dialysis solution Substances 0.000 description 18
- 229940024606 Amino Acids Drugs 0.000 description 17
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 17
- 229940049774 Extraneal Drugs 0.000 description 17
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 17
- 229920002774 Maltodextrin Polymers 0.000 description 17
- 239000002880 extraneal Substances 0.000 description 17
- 235000014633 carbohydrates Nutrition 0.000 description 16
- 239000008279 sol Substances 0.000 description 16
- 229920001353 Dextrin Polymers 0.000 description 15
- 239000004375 Dextrin Substances 0.000 description 15
- 235000019425 dextrin Nutrition 0.000 description 15
- 238000005227 gel permeation chromatography Methods 0.000 description 13
- 239000005913 Maltodextrin Substances 0.000 description 12
- 230000001965 increased Effects 0.000 description 12
- 229940035034 maltodextrin Drugs 0.000 description 12
- 210000004303 Peritoneum Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- -1 methyl ethyl Chemical group 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- 102000013142 Amylases Human genes 0.000 description 10
- 108010065511 Amylases Proteins 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 235000019418 amylase Nutrition 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000001124 Body Fluids Anatomy 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 230000002255 enzymatic Effects 0.000 description 8
- 150000004676 glycans Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 150000004804 polysaccharides Polymers 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 101700010703 sol-1 Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000004382 Amylase Substances 0.000 description 6
- 210000004379 Membranes Anatomy 0.000 description 6
- 210000003200 Peritoneal Cavity Anatomy 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 238000001631 haemodialysis Methods 0.000 description 5
- 230000000322 hemodialysis Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 239000008155 medical solution Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229940025131 Amylases Drugs 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 229940097362 Cyclodextrins Drugs 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- 210000003734 Kidney Anatomy 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 230000001926 lymphatic Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229920000310 Alpha glucan Polymers 0.000 description 3
- 229920000945 Amylopectin Polymers 0.000 description 3
- WMGFVAGNIYUEEP-WUYNJSITSA-N Amylopectin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]3[C@H](O[C@H](O)[C@H](O)[C@H]3O)CO)O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H]1O WMGFVAGNIYUEEP-WUYNJSITSA-N 0.000 description 3
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 3
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229960002160 Maltose Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229920002959 polymer blend Polymers 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000000284 resting Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 102000003925 1,4-alpha-Glucan Branching Enzyme Human genes 0.000 description 2
- 108090000344 1,4-alpha-Glucan Branching Enzyme Proteins 0.000 description 2
- 210000003567 Ascitic Fluid Anatomy 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 235000019749 Dry matter Nutrition 0.000 description 2
- 230000036826 Excretion Effects 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229910019093 NaOCl Inorganic materials 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 206010038428 Renal disease Diseases 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N Sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002902 bimodal Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000021258 carbohydrate absorption Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001175 peptic Effects 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2R,3S,4S,5R)-5-[[(2R,3S,4S,5R)-5-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- DPFYBZWSVVKNPZ-AQWIXGDGSA-N (3S,4S,6R)-2-[[(2R,4R,5R)-3,5-dihydroxy-4-methoxy-6-(methoxymethyl)oxan-2-yl]methoxymethyl]-6-ethyloxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)C(O)[C@@H](CC)OC1COC[C@@H]1C(O)[C@H](OC)[C@H](O)C(COC)O1 DPFYBZWSVVKNPZ-AQWIXGDGSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- BTXYOFGSUFEOLA-UHFFFAOYSA-N 2-amino-1-methylimidazol-4-ol Chemical compound CN1C=C(O)N=C1N BTXYOFGSUFEOLA-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229960003767 Alanine Drugs 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 229960004203 Carnitine Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229960002433 Cysteine Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101700011173 DLK1 Proteins 0.000 description 1
- 102100013696 DLK1 Human genes 0.000 description 1
- 229940119743 Dextran 70 Drugs 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N Isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UWTATZPHSA-N L-Asparagine Natural products OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N Myoinositol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N Ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 206010034668 Peritoneal infection Diseases 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 229960002429 Proline Drugs 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 101710042981 SHMT1 Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229960004799 Tryptophan Drugs 0.000 description 1
- 229960004441 Tyrosine Drugs 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000006903 Wheat Hypersensitivity Diseases 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 230000002475 laxative Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- RXVWSYJTUUKTEA-CGQAXDJHSA-N maltotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RXVWSYJTUUKTEA-CGQAXDJHSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001121 post-column derivatisation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental Effects 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Abstract
composition, comprising: a) maltose, glycerol, an amino acid, an oligopeptide, or a mixture of one or more thereof, in a content of 5 to 75 wt-% of the total weight of a)-d), b) glucose in a content of less than 1/2 the content of maltose, and in a total content of less than 5 wt-% of the total weight of a)-d), c) glucan molecules of DP 3 and DP 4, taken together, in a content of less than 1/2 of the content of maltose, d) glucan molecules of DP>4 in a content to give 100 wt-% together with a), b) and c), wherein glucan molecules of DP>10 are present in an amount of 15-80 wt-% of the total weight of a)-d), glucan molecules of DP>24 are present in an amount of 2-60 wt-% of the total weight of a)-d), glucan molecules of DP>55 are present in an amount of less than 15 wt-% of the total weight of a)-d), a method for producing it and its use as a medicament or for use in therapy, particularly in peritoneal dialysis. ight of a)-d), c) glucan molecules of DP 3 and DP 4, taken together, in a content of less than 1/2 of the content of maltose, d) glucan molecules of DP>4 in a content to give 100 wt-% together with a), b) and c), wherein glucan molecules of DP>10 are present in an amount of 15-80 wt-% of the total weight of a)-d), glucan molecules of DP>24 are present in an amount of 2-60 wt-% of the total weight of a)-d), glucan molecules of DP>55 are present in an amount of less than 15 wt-% of the total weight of a)-d), a method for producing it and its use as a medicament or for use in therapy, particularly in peritoneal dialysis.
Description
CARBOHYDRATE COMPOSITION FOR DIALYSIS
FIELD OF THE INVENTION
The present invention relates to an osmotically active composition, to an aqueous solution
comprising such composition and to the uses thereof.
BACKGROUND OF THE INVENTION
Specifically in the area of peritoneal dialysis, many works have been accomplished,
describing most different osmotically active compositions, including saccharide polymer
preparations, and their dialysis parameters in the clinic or in animal models, and different
measurement methods have been applied to establish parameters of their compositions. A
very well described medically applied saccharide polymer preparation for medical application
is Icodextrin.
Permanent dialysis treatment still causes significant side-effects, by interaction between
dialysis material (tubes, dialysis materials and solutions) and patient tissues.
Hemodialysis (HD) is the most commonly applied dialysis treatment. Respective side-effects
include inflammatory and cardiovascular complications, causing increased death rates.
Peritoneal dialysis (PD) represents an alternative to extra-corporal hemodialysis. It has the
advantage of being independent from heavy instrumentation, and can be done at home.
Furthermore, PD does not require drawing the patient’s blood out of the body. Instead, the
process uses the patient's peritoneal capillary tissue as a membrane, exchanging fluids and
dissolved substances (electrolytes, urea, glucose, and other small molecules) between blood
and the dialysate. A PD-Fluid (hereinafter: PDF) is introduced through a permanent tube into
the abdomen and, at the end of the peritoneal dialysis dwell, flushed out. Such dwells may
be carried out repeatedly, for various durations, at different time intervals. Maybe the most
important advantage of PD is, that it preserves residual kidney activities significantly, as
compared to hemodialysis (HD). This is not only of advantage to the patient allowing
excretion of certain amounts of body fluid by natural ways, but is also of high advantage to
peritoneal dialysis treatment itself, allowing a significant amount of excretion of slowly
metabolizable, small molecular weight components from peritoneal dialysis fluids.
11742412_1 (GHMatters) P111977.NZ
Common PDFs use glucose as osmotic agent at concentrations between 1 and 5 %, to
achieve transfer of fluid and toxic agent out of the blood into the dialysate. Glucose is a low
molecular weight constituent of blood (normal concentration around 0.1 %). High glucose
concentration of conventional PDFs leads to back diffusion of glucose, from the dialysate into
the patient’s blood stream, generating glucose overcharge, which is able to provoke
hyperglycemia. Hyperglycemia is specifically problematic, since many dialysis patients are
diabetic.
One way to address this problem is the use of saccharide polymers as an alternative osmotic
agent to replace glucose. Prior art of described polysaccharide is provided above.
The general advantage of glucose polymers is, that in the peritoneum, and in the blood, they
are not catabolized to glucose, but only to maltose and maltotriose. Both these molecules are
significantly less metabolized by the body, and are, to a large extend excreted through
residual renal function and/or through back dialysis into the dialysate of a next dwell.
Another advantage, specifically of poly-glucoses based PDFs is, that these solutions
maintain their own osmotic pressure. At the same time as some osmotic material gets lost by
resorption through the body, intraperitoneal amylases cut the polymer into smaller
saccharides, thereby increasing the osmotic pressure of the remaining intraperitoneal
maltodextrins. As a result, polysaccharide based PDFs can be administered at low osmolality
and will continue fluid resorption through ultrafiltration for many hours.
In 1986, Mistry et al. and Winchester et al., independently describe PDFs containing glucose
polymers in “Frontiers in Peritoneal Dialysis, eds: John F. Maher M.D., James F.
Winchester M.D., 1986, Springer Verlag, Heidelberg). Mistry describes a polymer preparation
containing glucose polymers of DP 1 to 10, Winchester describes a polymer preparation with
molecules of DP < 6 of less than 5 wt-%.
EP 0115911 discloses glucose polymers containing more than 15% of molecules of DP>12
wherein said preparation show an Mw 7 – 36kD, preferred 15 – 25 kD.
WO 8300087 A1 discloses glucose polymer preparations of an average DP of 4 to 10.
11742412_1 (GHMatters) P111977.NZ
EP 0076355 A2 discloses glucose polymer preparations for peritoneal dialysis containing at
least 85 wt-% of molecules less than DP 11, and at least 99 wt-% of molecules of less than
DP 26.
US 4,182,756 B1 discloses a substantially clear, nonpyrogenic, stable and sterile solution for
intravenous administration to human patients, said solution comprising at least 20% W/V of a
glucose polymer mixture having an average degree of polymerization of at least 4 and at
least 99% of its molecules less than 26 glucose units, at least 85% of its molecules less than
11 glucose units, and at least 20% of its molecules less than 4 glucose units.
US 6,248,726 B1 discloses a glucose polymer mixture, wherein at least 50% by weight of the
polymer is of molecular weight in the range 5000 to 30000, wherein at least 80% by weight of
the polymer is of molecular weight in the range 5000 to 50,000, wherein a weight average
molecular weight in the range of from 5000 to 100000, wherein a number average molecular
weight of less than 8000, and wherein the content of mono-, di-, and tri-saccharide
compounds present in the glucose polymer to be less than 5% by weight, and wherein the
content of glucose polymers with molecular weight greater than 100000 in the glucose
polymer is less than 5%.
GB 2 042 547 discloses starch hydrolysates, which optionally maybe hydrogenated, whose
glucid spectrum displays: a content of monosaccharides (DP = 1) of less than 14%, a
content of disaccharides (DP = 2) of less than 35%, a content of oligosaccharides of DP 4 to
DP 10 in the range of from 42% to 70%; and a content of polysaccharides of DP greater than
of less than 32%; all said percentages being percentages by weight, calculated on the
basis of dry matter.
Until now, high average molecular weight of saccharide polymers are used as osmotic
agents in PD, to reduce carbohydrate (hereinafter also abbreviated as: CHO) back diffusion
from the dialysis fluid into the blood of the patient. The drawback of such high molecular
weight polymer osmotic agents is that high MW molecules generate less osmotic pressure
than the same percentage of low MW molecules. A solution’s osmolality decreases as the
size of the osmotic active polymers increases (for a given w/v concentration). In order to
obtain comparable osmotic pressure, one has therefore to increase in the CHO
concentration. For example, Icodextrin at 7.5% in a physiological salt solution is barely above
physiological osmolality and speed of fluid ultrafiltration is slow. Due to a relatively constant
absorption of dialysate from the peritoneum through the lymphatic system, a high
11742412_1 (GHMatters) P111977.NZ
carbohydrate uptake during the dialysis dwell is the consequence. Despite this fact, recent
new developments look for even higher molecular weights of polysaccharides in PDFs, such
as US2012/02385A1.
Average osmolality of human blood is between 275 and 295 mOsm/kg, and is due to major
solutes in the blood, such as salts, other low molecular weight solutes and proteins.
Peritoneal fluids contain the major salts found in blood, as well as a pH buffer, but generally
no proteins. In any peritoneal treatment an osmotic pressure near to the human blood
osmolality is necessary to avoid rapid absorption of the peritoneal liquid into the body. In
peritoneal dialysis, one eventually needs to exceed the osmolality of blood, in order to
generate a fluid transfer from the patient's blood circulation compartment into the dialysis
fluid compartment. The necessary osmotic pressure in peritoneal therapeutic fluids (PTFs)
and peritoneal dialysis fluids (PDFs) is achieved by addition of "osmotic agents". Examples
for osmotic agents are glucose and maltodextrin or other mono- and/or polymeric saccharide
molecules, amino-acids, cyclodextrins, PEGs, derivatives of such compounds and mixtures
of such compounds and/or their derivatives. Osmotic pressure of a solution may be
measured in mOsm/kg. Currently marketed PDFs are applied at osmolalities between 280
and 500 mOsm/kg.
Extraneal®, is the only polysaccharide containing PDF marketed today. It contains icodextrin,
a maltodextrin with an Mw of 13 to 16 kD and an Mn of 5 to 6.5 kD (resulting in a Poly-D of
approximately 2.8). Extraneal® has a CHO concentration of 7.5%, necessary to reach iso-
osmolality with human blood and to initiate ultrafiltration. Upon instillation into the peritoneal
cavity, osmolality evolves to values between 290 and 325 mOsm/kg (De Wart et al. 2001.
Peritoneal Dialysis International, Vol. 21, pp. 269–274), within 8 to 12 hours, although the
dialysate volume increases slowly, and although average absorption of 30 to 40% of
icodextrin into the body has been reported during the dialysis dwell (Davies. Kinetics of
icodextrin. Perit Dial Int 1994; 14 (Suppl 2): S45 -50; Moberly et al. 2002. Kidney
International, Vol. 62, Supplement 81 (2002), pp. S23–S33). Progressive digestion of
icodextrin is occurring as well in the peritoneum as in the blood stream by low concentrated
amylases (Moberly et al. 2002).
A major disadvantage of Icodextrin is the very slow ultrafiltration, and therefore 8 to 12 hour
dwells are usually applied. Therefore, in most cases, Extraneal® cannot be applied as a
monotherapy, but only as a once-a-day dialysis application of 8 to 12 hours, and the use of
Icodextrin in automated dialysis has also been questioned (Freid et al. 2008). Short dialysis
11742412_1 (GHMatters) P111977.NZ
dwells to efficiently reduce body fluid, today, are therefore carried out applying glucose-
based PDFs in most cases.
So far Extraneal® is generally applied once a day, and only experimentally or exceptionally
twice a day, because of the long dwell time and of concerns of polysaccharide absorption.
An experimental glucose polymer preparation was described by Leypoldt et al. (2013,
Perotoneal Dialysis International, Vol.33, pp 124-131) having Mw of 6.4kD the Mn 2.8 kD.
The authors fractionated Icodextrin, in one low average molecular weight preparation (weight
average molecular weight Mw 6.4kD, number average molecular weight Mn 2.8kD) and one
high molecular preparation (Mw 18.8kD, Mn9.4kD). Both preparations were tested, at the
concentration of 7.5%, in a rabbit model with permanent catheters. The authors suggest, in
this model, that a 240 min dwell corresponds to a long dwell in PD patients. In this
publication the authors report NUF for the low molecular weight fraction between roughly 60
and 85 ml, and NUF for the high molecular weight fraction between roughly 40 and 45 ml, for
an initial dialysate volume of 100 ml, after a 240 min dwell, and conclude that a low
molecular weight glucose polymer is more effectively generating UF and produces a higher
UF efficiency, those factors come at the expense of the polymer being more readily absorbed
from the peritoneal cavity. No results on concentrations lower than 7.5% were reported. No
NUF Volumes for shorter delays than 240 minutes were reported.
Although there was a difference between the low Mw Fraction and the high Mw
fraction, no data comparing the low molecular weight solution and Icodextrin was reported.
Finally, to increase Icodextrin PDF solution osmotic efficacy, bimodal PDFs have been made,
combining Icodextrin with glucose, but then again such solution were not glucose free any
longer (Dousdampanis et al. 2013,Internat. J. of Nephrology, Vol.2013, Article ID424915,
Freida et al. 2008, Kidney International Vol. 73, p S102-S111).
An aspect of the invention was to provide a composition, that fulfils one or more of the
following functions:
- shows higher osmolality than Icodextrin, at lower carbohydrate concentration
- increases net ultra filtration as compared to icodextrin, at such lower carbohydrate
concentration .
- enables reasonable net ultrafiltration during short dialysis dwells (particularly 2 to 4
hours in humans).
11742412_1 (GHMatters) P111977.NZ
- shows a higher ratio of Net-Ultrafiltration Volume over carbohydrate absorption at such
reduced carbohydrate concentrations, as compared to Icodextrin.
- contains glucose at a final concentration of less than 0.2% w/v of the final solution.
- contains a sufficient concentration of high molecular weight components to sustain
positive osmotic pressure during the entire dwell.
SUMMARY OF THE INVENTION
The present invention provides with a composition, comprising or consisting of:
a) a compound that is selected from the group consisting of maltose, glycerol, an amino
acid, an oligopeptide, or a mixture of one or more thereof, preferably maltose, in a
content of 5 to 75 wt-% of the total weight of a)-d), preferably 8 – 65 wt-%, more
preferably 10 - 55 wt-%,
b) glucose in a content of less than 1/2, preferably less than 1/3, the content of a), and in a
total content of less than 5 wt-% of the total weight of a)-d),
c) glucan molecules of DP 3 and DP 4, taken together, in a content of less than 1/2,
preferably less than 1/3, of the content of a),
d) glucan molecules of DP>4 in a content to give 100 wt-% together with a), b) and c),
wherein
- glucan molecules of DP>10 are present in an amount of 15 - 85 wt-%, preferably 20-80
wt-%, further preferably 35-80 wt-%, of the total weight of a)-d),
- glucan molecules of DP>24 are present in an amount of 2 – 60 wt-%, preferably 4 – 58
wt-%, more preferably 5 - 56 wt-% of the total weight of a)-d),
- glucan molecules of DP>55 are present in an amount of less than 15 wt-% of the total
weight of a)-d), preferably less than 12 wt-%.
In one aspect, the present invention provides a composition, comprising:
a) a compound that is selected from the group consisting of maltose, glycerol, an
amino acid, an oligopeptide, or a mixture of one or more thereof, in a content of 5
to 75 wt-% of the total weight of a)-d),
b) glucose in a content of less than 1/2 the content of a), and in a total content of less
than 5 wt-% of the total weight of a)-d),
c) glucan molecules of DP 3 and DP 4, taken together, in a content of less than 1/2 of
the content of a),
11742412_1 (GHMatters) P111977.NZ
d) glucan molecules of DP>4 in a content to give 100 wt-% together with a), b) and
wherein
- glucan molecules of DP>10 are present in an amount of 15-80 wt-% of the total
weight of a)-d),
- glucan molecules of DP>24 are present in an amount of 2-60 wt-% of the total
weight of a)-d),
- glucan molecules of DP>55 are present in an amount of less than 15 wt-% of the total
weight of a)-d).
The weight average molecular weight of a)-d), taken together, may be Mw 0.8 - 15kD,
preferably Mw 1.0 – 10kD, more preferably Mw 1.2 – 6.2 kD or 1 – 6.2 kD, more preferably
1.4 – 6 kD, more preferably 1.6 to 5.8 kD
The number average molecular weight of a)-d), taken together, may be Mn 0.2 - 3 kD,
preferably Mn 0.3 – 3 KD, more preferably Mn 0.5 - 3 kD or 0.7 – 3 kD, preferably 0.8 – 2.7
kD, more preferably 0.9 – 2.6 kD.
These Mw and Mn values can be combined in any combination, for example Mw 1 – 6.2 kD
and Mn 0.7 – 3 kD.
Maltose may be used singly in a). Maltose may be partly or completely replaced by other low
M molecules that do not impact insulin secretion, such as mentioned amino-acids,
oligopeptides, and/or glycerol. Such compounds are presently applied examples for low
molecular weight osmotic agents.
Features indicated with the attribute “preferably”, “more preferably”, “even more preferably”
etc. can be combined in any combination, also with features not indicated with any of these
attributes. For example, a feature indicated with the attribute “preferably” may be combined
with a feature not comprising any of such attributes, or with a feature comprising the attribute
“more preferably” etc.
The sign “-“ in connection with numbers and units indicates ranges, if not otherwise
indicated.
11742412_1 (GHMatters) P111977.NZ
The invention also provides with a liquid aqueous composition, comprising such composition
and water.
In a further aspect the invention provides with said composition or said liquid aqueous
composition for use as a medicament or for use in therapy, wherein specific uses are
mentioned in the detailed description.
The invention also provides with a method for producing a liquid aqueous composition as
mentioned above, comprising
- preparing an aqueous solution of starch, having a solids content of from 10 wt-% to 60
wt-% by weight;
- gelatinization, by treating said solution successively with a specific combination of
enzymes chosen from amyloglucosidase and/or amylase,
- purifying the solution,
- fractionating the solution in such a way as to eliminate or decrease molecular-weight
saccharide fractions having a molecular weight higher than 40000 D, preferred higher
than 18 kD, and to recovering the other fractions,
- adding a compound that is selected from the group consisting of maltose, glycerol, an
amino acid, an oligopeptide, or a mixture of one or more thereof, and optionally glucose,
Thereby, particularly by fractionation and by addition of maltose, glycerol, amino-acids or
oligo-peptides, optionally glucose, a composition of the invention is obtained, or obtained in
the solution.
The invention also provides with a container or kit comprising at least one compartment,
containing a liquid aqueous composition as mentioned above or a composition of the
invention.
One or more of the following benefits can be reached with the present invention, in the
general or in specific embodiments
- The composition show osmotical activity. In this sense the composition is also called
osmotically active composition
- the liquid composition contains no more glucose than the physiological level (0.2% max)
- highly reduced fractions of saccharide with high molecular weight (above 40 kD, further
preferred above 18 kD),
11742412_1 (GHMatters) P111977.NZ
- a composition of lower average molecular weight than Icodextrin. The composition, as
compared to icodextrin, has significantly reduced high molecular weight saccharides,
above 18 and 40 kD respectively.
- Cytotoxic effects of Icodextrin on primary human mesothelial cell-cultures are reduced. It
is believed that such cytotoxic effects at least partly related to high molecular weight
saccharide fractions of Icodextrin. The present invention excludes or reduces potentially
cytotoxic, high molecular weight fractions (preferably higher 40kD of less than 0.6 wt-%,
preferred less than 0.3 wt-%, even more preferably higher 18kD less than 1.5%, of the
entire composition.
- the composition of the invention, if applied as the sole osmotic agent to PTFs or PDFs in
the presence of physiologic concentration of salts, is able to generate iso-osmolality or to
generate hyper-osmolality (higher than physiological Osmolality of human blood) at
concentrations of 2 - 7.2 % total CHO (w/v), preferably 2.2 and 7 %, preferably 2.4 to
6.8%, preferably 2.6 to 6.6% total CHO (w/v).
- In accordance with this invention, a composition is provided, acting as an osmotic agent,
in medical applications, preferred PTFs, preferred PDFs. The composition, alone, or
together with a low molecular weight osmotic agent, is able to generate sufficiently high
osmolality to cause diffusion of water and waste products across the peritoneum after
infusion of the peritoneal dialysis fluid into the peritoneal cavity of a patient. In addition to
one osmotic agent, or to a combination of osmotic agents, such a medical application
fluid contains amounts of various physiologically important electrolytes, comparable to
those in human body fluids.
As compared with a currently applied maltodextrin (icodextrin) in a commercialized PDF
(Extraneal®, Baxter), in terms of osmotic agent efficacy, the composition of the invention and
their derivatives can surprisingly be distinguished from Icodextrin by one or more of the
following effects:
- a significantly increased transcapillary ultrafiltration (TCUF) during short dwells. TCUF is
defined in the detailed description.
- a significantly increased net-ultrafiltration (NUF) during short dwells. NUF is defined in
the detailed description.
- a significantly increased TCUF per unit of time (ml/h).
- a significantly increased NUF per unit of time (ml/h).
- a significantly increased TCUF per unit of carbohydrate (CHO) absorption (ml/g).
- a significantly increased NUF per unit CHO concentration (ml/g).
- lower overall CHO concentration in the PDF.
11742412_1 (GHMatters) P111977.NZ
- The results obtained in the frame of this invention suggests the possibility of applying our
solution twice, three or four times a day, because of shortened dwell time, lower CHO
concentration and the resulting decreased CHO absorption per dwell. Such increased
ultrafiltration shall allow, in certain cases, saccharide-polymer based PD as a mono-
therapy. An increased part of saccharide polymer-based PD during the day would be of
great benefit, further reducing current problems of hyperglycemia, in the case of diabetic
PD patients.
- In accordance with this invention, compositions of the invention enhance ultrafiltration
efficacy as described above because of the following characteristics
a) being an efficient osmotic agent during short dialysis dwells
b) having a high reservoir of cleavable bonds to allow maintenance of osmolality during
long dwells.
DEFINITIONS:
For description of concentrations of dissolved solid components of a solution (e.g. a glucose
polymer mixture in a peritoneal dialysis solution), in this patent application, it was applied
Volume percentage (% w/v) corresponding to an amount by weight of a given compound by
volume of solution, e.g. 10% w/v corresponds to 10 g of referred compound in 100ml of final
solution, which corresponds to a commonly applied standard in pharmacological descriptions
of such solutions.
In this application the term “glucan” means any composition or polydisperse mixture of
oligomeric and/or polymeric molecules ( = glucan molecules) consisting of D-glucose
monomers, wherein the D-glucose monomers are linked by glycosidic bonds. Instead of the
term “glucan” the term “glucose polymer” may be used. The degree of polymerization (DP) of
the glucan molecules is per definition in the present invention at least 3. A dimer (DP 2) is
called in the present invention “maltose”, the monomer is called “glucose”, wherein these
terms have the known meaning.
The glucan of the invention is preferably an “α-glucan”. The term “α-glucan” means a glucan
wherein the D-glucose monomers are linked by α-glycosidic bonds.
The term “dextrin” means a glucan comprising α-1,4 and/or α-1,6 glycosidic bonds,
preferable both. Dextrins may include maltodextrins and cyclodextrins. A dextrin may be
11742412_1 (GHMatters) P111977.NZ
obtained, without limitation, by starch hydrolysis or any other procedure. A special dextrin is
icodextrin or starch hydrolysis products of molecular weights between 180 Daltons and 200
kilo-Daltons (kD).
The term “maltodextrin” means a dextrin not comprising cyclodextrins. In a special case
maltodextrin is icodextrin, or other linear or branched non-cyclic dextrins of molecular
weights between 180 Daltons and 200 kilo-Daltons. Maltodextrins can be generated from
limited hydrolysis from starch. Starch is composed from two kinds of glucose polymers:
amylose, which are straight chains of glucose polymers bound by α(1,4) glycosidic bonds,
and amylopectin containing around ten percent of α(1,6) glycosidic bonds, introducing
branching into the saccharide polymer. As a result of initial composition of the starch, of
conditions of hydrolysis, or of addition of specific enzymes, the resulting maltodextrin may
have different degrees of branching (for example between 0 and 40 %).
The term “dextran” means an α-1,6-glucan with α-1,3-branches.
The term "derivative" of a glucan or glucan molecule or “derivatized” means modified
molecules or molecule populations derived from enzymatic, chemical and/or physical
modification. For example, polymers bonds may be hydrolyzed or supplementary bonds may
be generated, or functional groups in the glucan, particularly hydroxyl groups may be
derivatized or substituted.
Starch derivatives mean modified starches derived from the enzymatic, chemical and/or
physical modification, in one or more steps, of starch.
The term “oligipeptide” means a peptide composed of 2-10 aminoacids. So, the term
“oligipeptide” encompasses bi-amino acids, i.e. a peptide composed of two amino acids. The
oligopeptide is preferably a bi-amino acid, so that the term oligopeptide can in a specific
embodiment be replaced by the term bi-amino acid.
Molecular weight measurements can be done by Gel Permeation Chromatography (GPC),
particularly GPC-RI, or ion exchange chromatography or a combination of both. As far as
glucans are concerned, GPC or GPC-RI are preferred. As far as amino acids or peptides are
concerned, ion exchange chromatography is preferred. In order to obtain results for
(average) molecular weights in a composition comprising glucans as well as glycerol, an
amino acid, an oligopeptide, or a mixture of one or more thereof, molecular weight of glucans
11742412_1 (GHMatters) P111977.NZ
and the molecular weight of the other component can be determined singly and then the
results be combined to obtain for example the average molecular weight for components a)-
d) of the composition. So, in case of such composition, the method for determining Mw and
Mn is preferably a combination of GPC or GPC-RI and ion exchange chromatography. If
component a) is maltose, molecular weight can be determined in one sample, preferably with
GPC or GPC-RI.
Molecular weight (M, unit g/Mol) may be calculated for any molecule or polymer. For
example, the molecular weight of a glucan molecule is given by
M (glucan molecule of i units) = 180 g/Mol + (i-1)*162 g/Mol,
wherein 180 g/Mol is the molecular weight of glucose and 162 g/Mol the molecular weight of each
added glucose unit, after polymerization through hydrolysis.
No single number can adequately characterize the molecular weight of a preparation of
saccharides. Therefore, various descriptors are used. The most commonly used are the
"weight average molecular weight" (Mw) and the "number average molecular weight" (Mn):
Mw = Ʃ(n *M ) / Ʃ(n*M)
i i i i
Mn = Ʃ(n *M) / Ʃ(n )
i i i
where n is the number of molecules of molecular weight M. Mw is particularly sensitive to
changes in the high-molecular-weight content of the saccharide preparation whilst Mn is largely
influenced by changes of the low molecular weight molecules in the sample.
The molecular weight of glycerol is 92 Dalton, or 92 g/Mol.
Amino-acids have molecular weight between 75 and 205 g/Mol.
Oligopeptides have the molecular weight of each of their composing amino-acids, in
summary, subtracted by 18 g/Mol for each peptic bond, corresponding to the loss of 1 water
molecule during peptic bond formation.
Average M (Mw and Mn) of a mixture of amino acids and/or peptides may be calculated the
same way as Mw for a mixture of saccharides.
Mw = Ʃ(ni*Mi ) / Ʃ(ni*Mi)
Mn = Ʃ(n *M) / Ʃ(n )
i i i
The amount of individual amino-acids or oligopeptides within the mixture is either known or
summed up.
11742412_1 (GHMatters) P111977.NZ
Average Mw (Mw and Mn) of a mixture of Saccharides and non-saccharides, (e.g. can be
calculated the same way than Mw of saccharides or amino-acids
Mw = Ʃ(n *M ) / Ʃ(n*M)
i i i i
Mn = Ʃ(n *M) / Ʃ(n )
i i i
The amounts of all the different components of the mixture and their molecular weights are
either known or summed up. Often, composition of an amino-acid mix is analyzed and
communicated by the supplier, else they can be determined as stated hereunder.
Reliable techniques to analyze composition of amino-acids mixes or peptides imply ion
exchange chromatography, with post column derivatization (e.g. with nin-hydrin Anders JC.
Advances in amino acid analysis. BioPharm Int.2002;4:32–39.).
A "Poly-Dispersion Index" (Poly-D) of a sample may be calculated, as the ratio of Mw / Mn.
The degree of polymerization of a polymer molecule is defined as
DP = M (polymer molecule)/ M (monomer) wherein in case of glucan M (monomer) is 162
g/mol.
So, every molecular weight (M) of glucan molecule can be expressed as DP and vice versa.
The terms DPw and DPn mean the weight average degree of polymerization and the number
average degree of polymerization, and are defined as follows:
DPw = Mw/ M (monomer)
DPn = Mn/ M (monomer)
Molecular weights and degrees of polymerization, also average values thereof, are
preferably measured by gel permeation chromatography (GPC), preferably by gel
permeation chromatography with refractive index (RI) detection (GPC-RI). Ion exhange
chromatography is also possible, particularly in case of peptides/amino acids. A specific
method is further described in the examples.
The amount of a molecular fraction with a given molecular weight range can be indicated in
many different ways. A very common and useful way to do so, is to express the amount of
11742412_1 (GHMatters) P111977.NZ
such fractions as weight percentages of the entire composition, no matter the final
concentration at which such composition shall be applied in the final solution. In the present
invention we express weight percentage of components a), b), c) or d) in percent of the total
weight of a)+b)+c)+d). The total weight of a)+b)+c)+d) is also called “total CHO”.
Percentages related to the total weight of a)+b)+c)+d) are calculated on the basis of dry
matter.
Weight percentages of glucan molecules, or fractions of glucan molecules, the fractions
defined by DP or otherwise, within a glucose polymer preparation can be determined by
GPC, particularly GPC-RI. Weight percentage of a glucan molecule or fraction can
particularly be determined by determining the area for said glucan molecule/fraction in a
GPC chromatogram and determining its relation to the area of the species, e.g. all glucan
molecules, to which it shall be set in relation. Knowing the area of all glucans within the
composition of the invention then allows to calculate weight percentages of glucan
molecules, or fractions of glucan molecules, within a)-d) (wherein a)-d) are as defined
above). For example:
wt-% of fraction or molecule or interest
= [(area of molecule or fraction of interest)/(area of total CHO)] * 100
wherein the area means the area in the GPC-chromatogram.
The detailed procedure of determination of percentages of molecules or fractions is known to
skilled persons in this field and it is not necessary to limit the method on details. As known, in
GPC, the concentration by weight of polymer in the eluting solvent may be monitored with a
detector. The molecular weight can be determined with molecular weight standards. The
examples describe measures, that may be combined with the above procedure: total amount
or concentration of a glucose polymer preparation may correspond to the area under the
curve of a GPC chromatogram after background-substraction, followed by a calibration using
molecular weight standards, particularly Icodextrin, maltose and glucose standards.
Quantification of molecular weight fractions or molecules may be assessed by using
molecular weight standards, such as dextran molecular weight standards and Icodextrin as a
comparative standard.
In a liquid composition, the weight percent of components may alternatively be defined on
basis of the whole mass of the whole liquid composition.
11742412_1 (GHMatters) P111977.NZ
In this invention the term “Physiological Concentrations of Salts” is used to describe the
following concentrations:
• sodium at a concentration from about 100 to about 150 mEq/L;
• potassium at a concentration from about 0 to about 10 mEq/L;
• calcium at a concentration from about 0 to about 10 mEq/L;
• magnesium at a concentration from about 0 to about 10 mEq/L;
The term "peritoneal therapeutic fluid" (PTF), as used in the present application, refers to an
aqueous solution comprising physiological amounts of various electrolytes in concentrations
comparable to those found in blood. Common peritoneal dialysis fluids may comprise:
• sodium at a concentration from about 100 to about 150 mEq/L;
• potassium at a concentration from about 0 to about 10 mEq/L;
• calcium at a concentration from about 0 to about 10 mEq/L;
• magnesium at a concentration from about 0 to about 10 mEq/L;
• an "Osmotic Agent", such as glucose and/or maltodextrin or other mono- and/or polymeric
saccharide molecules, amino-acids and peptides, cyclodextrins, polyethelyne glycols (PEGs),
glycerol, dextranes, and other biocompatible compounds at concentrations high enough to
generate osmotic pressure, derivatives of such compounds and mixtures of such compounds
and/or their derivatives, with the Osmotic Agent being at a final combined concentration
between 0.5 and 20 %.
A PTF may be applied into the peritoneum in order to fulfill treatment of the peritoneum itself
or systemic treatments. Examples for treatment of the peritoneum are chemotherapies against
peritoneal cancer, or against peritoneal infections. A very common example for systemic
treatment by peritoneal fluids is peritoneal dialysis, where low molecular waste products are
eliminated from the blood circulation, in most cases because of renal malfunction.
A "peritoneal dialysis fluid" (PDF) is a liquid mixture to be introduced and maintained in the
peritoneal cavity of a patient in need of dialysis, to cleanse the blood and balance its
constituents, for a time period of for example 1 to 16 hours, sufficient to remove blood waste
products and water from the patient. At the end of said period, a "dialysate" is removed from
the patient's peritoneal cavity.
Peritoneal dialysis dwell times vary from less than 2 hours, for example in automated peritoneal
dialysis (ADP); over 4 to 6 hours, for example in continuous ambulatory peritoneal dialysis
11742412_1 (GHMatters) P111977.NZ
(CAPD); to 8 to 12 hours in long dialysis dwells, for example whole day or whole night dwells.
In this application, dwells of up to 6 hours are referred to as short PD dwells, whereas dwells
of 8 hours and longer are referred to as long dwells.
The term "ultra-filtration" (UF) describes exchange of fluids and dissolved substances (e.g.
fluid, electrolytes, urea, creatinin, glucose, and other small molecules) per unit of time. Ultra-
filtration during dialysis occurs from the blood compartment into the peritoneal compartment,
containing the dialysate. On the other hand, solutes and liquid from the dialysate may back
transfer into the patient’s system, either by lymphatic absorption, or by back-ultra-filtration, of
small molecules or liquid from the dialysate into the blood.
In the context of the present invention, the term transcapilary ultrafiltration corresponds to all
body fluids that transfers from the body into the dialysis fluid, during the peritoneal dialysis
dwell.
The term net-ultrafiltration (NUF), is established subtracting the recovered dialysate Volume
(RDV) at the end of the dialysis dwell, from the volume of initially administered PD Fluid (IPFV):
NUF = IPFV – RDV
NUF is the result of transcapillary ultrafiltration (TCUF) (out of the blood into the dialysis fluid)
versus lymphatic absorption (LA) of dialysis fluid (out of the peritoneal cavity into the body):
NUF = TCUF – LA.
Net ultra-filtration may be positive (fluid elimination from the patient into the dialysate), which
corresponds to one of the aims of dialysis or negative (overall fluid uptake from the peritoneum
into the patient), e.g. when the osmotic pressure was not sufficiently sustained over the time
of the dialysis dwell.
Lymphatic absorption (LA) can be assessed based on the initially administered PD Fluid
Vol(PDF) multiplied by the quantitative loss of an intra-peritoneally administered volume
marker such as dextran 70:
( � � − � � )
LA(ml) = * Vol(PDF)i
( � � )
Transcapilary Ultra-filtration (TCUF) can then be calculated by addition of Lymphatic
absorption and net-ultrafiltration:
TCUF = NUF + LA.
11742412_1 (GHMatters) P111977.NZ
The term “total CHO” is applied to the total amount of carbohydrates present in a PTF.
The term “CHO absorption” is applied to describe the total “amount of carbohydrates” (CHO)
absorbed by the patient from the PDF in the peritoneum, during a peritoneal dialysis (PD)
dwell. Carbohydrate absorption is assessed as means of metabolizable osmotic agent
absorbed by the body during a dialysis dwell. It is established by subtracting total carbohydrate
amount of recovered dialysate from total carbohydrate amount of initially administered PD fluid.
Glycerol, which is a carbohydrate derivative, is also regarded as a carbohydrate, and, if
applied, is accounted within the terms “total CHO” and “CHO- absorption”.
Strictly speaking, amino-acids and peptides are not carbohydrates, since they also contain
Nitrogen atoms. But since the interest of total CHO and CHO absorption is mainly to estimate
metabolizable components within the PTF, and in order of simplicity, we will account for amino-
acids and oligopeptides within the terms ‘total CHO” and “CHO absorption”.
The term “Rate of NUF per CHO absorption” is applied to describe the ratio of the NUF Volume
(ml) over the total weight of CHO absorption (mg), during a dialysis dwell.
"Near to physiological blood pH" corresponds to a pH of 6.5 to 8, preferably of 6.8 to 7.7, more
preferably of 7 to 7.5.
Hereinafter, molecular weight ranges are described. Each of the ranges comprises one or
more chain lengths of glucan molecules, expressed in DP. The ranges are intended to facilitate
a comparison with prior art, wherein such ranges are indicated. Moreover, these ranges are
used to define specific embodiments of the invention, as described in the detailed description.
Please note that the boundaries of these ranges are rounded values. Since it has been used
in many publications and patents as such, we integrate DP information in our analyses of
anterior publications and patents on glucose polymers in the following manner.
DP molecular weight(D) molecular weight range(D)
1 180 <200
2 342 200-400
3 504 400-600
4 667 600-750
11742412_1 (GHMatters) P111977.NZ
829 750-900
6 991 900-1000
7 1153 1000-1250
8 1315 1250-1400
9 1477 1400-1500
1639 1500-1750
11 1802 1750-1900
12 1964 1900-2000
13 2126 2000-2250
14 2288 2250-2400
2450 2400-2500
16 2612 2500-2750
17 2774 2750-2800
18 2937 2800-3000
19 3099 3000-3250
3261 3250-3300
21 3423 3300-3500
22-24 3500-4000
-27 4000-4500
28-30 4500-5000
31-33 5000-5500
34-36 5500-6000
37-39 6000-6500
40-43 6500-7000
44-46 7000-7500
47-49 7500-8000
50-55 8000-9000
56-61 9000-10000
62-67 10K-11K
68-73 11K-12K
74-76 12K-12.5K
77-80 12.5K-13K
81-86 13K-14K
87-92 14K-15K
93-98 15-16K
99-104 16K-17K
11742412_1 (GHMatters) P111977.NZ
105-110 17K-18K
111-117 18K-19K
118-123 19K-20K
124-129 20-21K
DETAILED DESCRIPTION OF THE INVENTION
Embodiments described in this detailed description can be combined in any combination sub-
combination in this invention.
The composition may be a bi-modal composition, which means that in the molecular weight
distribution two peaks are present, one peak in a smaller molecular weight region and one and
a higher molecular weight region. In this aspect, the composition may comprise a glucan
(preferably an alpha-glucan) polymer preparation, preferentially a maltodextrin or a
maltodextrin derivative, and as further components may comprise one or several of: maltose,
glucose, glycerol, amino-acid, and/or oligopeptide, which may be added to the polymer
preparation. For example, in peritoneal dialysis, a bi-modal osmotic agent maybe a
maltodextrin preparation (for example Icodextrin), to which maltose, glucose, glycerol, amino-
acid, and/or oligopeptide, is added.
Even if the singular term “amino acid” or “peptide is used herein, the plural, particularly a
mixture of these, is encompassed.
The term “polymer” is intended to encompass also “oligomers”.
A preferred glucan is dextrin, dextran and/or derivatives of such. A preferred dextrin is
maltodextrin.
The composition may be a solid composition. The composition may be a dry composition.
The composition may be obtained by drying a liquid aqueous composition which can be
obtained by a method of the invention as described hereinafter.
The composition of the invention may comprise further ingredients, such as one or more of:
salts, other compounds than defined in a)-d), trace elements, enzymes, other osmotic
11742412_1 (GHMatters) P111977.NZ
agents, and/or active pharmaceutical ingredients. Preferably, components a)-d) is at least 90
wt-% of the total composition, even more preferably at least 95 wt-%, more preferably at
least 98 wt-%.
In a further related aspect claimed compositions may be mixed with other osmotic agents.
The glucan molecules of DP>10. DP>24, DP>55, or still further glucan molecules mentioned
below with higher DP, are part or fractions of component d) which are the glucan molecules
with DP>4.
If ranges of components b) (glucose) or c) (glucan molecules of DP 3 and DP 4,) are
indicated with the expression “less than”, a lower limit of such range is more than 0 wt-%,
preferably at least 0.01 wt-% of the total weight of a)-d), more preferably at least 0.1 wt-% of
the total weight of a)-d). So, components b) and c) are always present.
If ranges of other components are indicated with the expression “less than”, a lower limit of
such range is preferably more than 0 wt-%, more preferably at least 0.01 wt-% of the total
weight of a)-d), even more preferably at least 0.1 wt-% of the total weight of a)-d).
Mw of the composition is Mw 0.8 - 15kD, preferably Mw 1 – 10kD, more preferably 1.2 – 6.2
kD or 1.0 – 6.2 kD, more preferably the range of 1.4 – 6 kD, more preferably 1.6 to 5.8 kD.
Other possible ranges are 1.3 – 6 kD, 1.5 - 5.8 kD, 1.5 to 5 kD.
These ranges of Mw can be combined with any ranges of Mn. Mn of the composition is
preferably 0.2 - 3 kD, preferably the range of 0.3 to 3 KD, more preferably 0.5 to 3 KD or 0.7-
3 kD, more preferably 0.8 – 2.7 kD, more preferably 0.9 – 2.6 kD. Other ranges are 1 - 2.7
kD, 1.2 - 2.5 kD.
In one embodiment of the composition, glucan molecules of DP>111 are present in an
amount of less than 1.5 wt-% of the total weight of a)-d).
In one embodiment of the composition, glucan molecules of DP>246 are present in an
amount of less than 0.6 wt-% of the total weight of a)-d).
In one embodiment, the composition comprises the glucose in a content of less than 1/3 the
content of ingredient a) of the composition (a compound that is selected from the group
11742412_1 (GHMatters) P111977.NZ
consisting of maltose, glycerol, an amino acid, an oligopeptide, or a mixture of one or more
thereof), specifically less than 1/3 the content of maltose, if maltose is used as ingredient a).
In one embodiment, the composition comprises the glucan molecules of DP 3 and DP 4,
taken together, in a content of less than 1/3 of the content of ingredient a) of the composition
(a compound that is selected from the group consisting of maltose, glycerol, an amino acid,
an oligopeptide, or a mixture of one or more thereof), specifically less than 1/3 the content of
maltose, if maltose is used as ingredient a).
In one embodiment, the composition comprises ingredient a) of the composition (a
compound that is selected from the group consisting of maltose, glycerol, an amino acid, an
oligopeptide, or a mixture of one or more thereof), particularly maltose, in a content of 8 to 65
wt-% of the total weight of a)-d).
In one embodiment, the composition comprises the glucan molecules of DP>4 in a content of
more than 16 wt-%, preferably more than 21 wt-% of the total weight of a)-d).
In one embodiment, the content of glucan molecules of DP 3 and DP 4, taken together, is
less than 15 wt-% of the total weight of a)-d), more preferably less than 10 wt-% of the total
weight of a)-d), even more preferably less than 5 wt-% of the total weight of a)-d).
In one embodiment, the content of glucan molecules of molecular weight of 0.8 to 1.5 kD, or
DP5-DP9, is 4 - 39 wt-%, preferably 6 - 23 wt-%, of total CHO.
In one embodiment, the content of glucan molecules of molecular weight of 1.5 to 4.5 kD, or
DP10-DP27, is 16 - 60 wt-%, preferably 20 - 60 wt-%, of total CHO.
In one embodiment, the content of glucan molecules of molecular weight of 4.5 to 9 kD, or
DP28 – DP55 is less than 48 wt-%, preferably less than 45 wt-%, of total CHO.
In one embodiment, the content of glucan molecules of molecular weight smaller than 9 kD,
or DP<55, is more than 85 wt-% of total CHO, more preferably more than 90 wt-% of total
CHO.
11742412_1 (GHMatters) P111977.NZ
In one embodiment, the content of glucan molecules of molecular weight of 0.8 - 4.5 kD, or
DP5 – DP27, is more than 18 wt-%, preferably more than 25 wt-%, even more preferably
more than 30 wt-%, of total CHO.
In one embodiment, the content of glucan molecules of DP 3 and 4 is less than 30 wt-%,
preferably 2 to 26 wt-%, more preferably 2 to 15 wt-%, even more preferably 2 to 10 wt-%,of
total CHO.
In one embodiment, the content of glucan molecules of DP 5 and 6 is less than 35 wt-%,
preferably 1 to 15 wt-%, of total CHO.
In one embodiment, the content of glucan molecules of DP 7 to 10 is less than 35 wt-%, pref
1 to 18 wt-%, of total CHO.
In one embodiment, the content of glucan molecules of DP < 10 is 15 - 85 wt-%, preferably
-80 wt-%, of total CHO.
In one embodiment, the content of glucan molecules of DP>25 is 1.9 – 59.5 wt-%, preferably
3.9 – 57.5 wt.-%, preferably 4.9 – 55.8 wt-% of total CHO.
In one embodiment, the content of glucan molecules of DP>30 is less than 59 wt-%,
preferably less than 55 wt-%, more preferably less than 50 wt-% of total CHO.
In one embodiment, the content of glucan molecules of DP>111 is less than 1.5 wt-% of total
CHO.
In one embodiment, the content of glucan molecules of DP>246 is less than 0.6 wt-% of total
CHO.
As mentioned before, features of this specification can be combined in any manner and any
number. In a very specific embodiment, which reflects only one possible combination, the
present invention provides with a composition, comprising:
a) a compound that is selected from the group consisting of maltose, glycerol, an amino
acid, an oligopeptide, or a mixture of one or more thereof, preferably maltose, in a
content of 5 to 75 wt-% of the total weight of a)-d), preferably 8 – 65 wt-%, even more
preferably 10 - 55 wt-%,
11742412_1 (GHMatters) P111977.NZ
b) glucose in a content of less than 1/2, pref less than 1/3, of the content of a), and in a
total content of less than 5 wt-% of the total weight of a)-d),
c) glucan molecules of DP 3 and DP 4, taken together, in a content of less than 1/2,
preferably of less than 1/3, of the content of a),
d) glucan molecules of DP>4 in a content to give 100 wt-% together with a), b) and c),
wherein
- glucan molecules of DP 3 and 4 are present in an amount of less than 30 wt-%,
preferably 2 to 26% wt-%, of the total weight of a)-d),
- glucan molecules of DP 5 and 6 are present in an amount of less than 35 wt-%,
preferably 1 to 15 wt-%, of the total weight of a)-d),
- glucan molecules of DP 7 to 10 are present in an amount of less than 35 wt-%,
preferably 1 to 18 wt-%, of the total weight of a)-d),
- glucan molecule of DP < 10 are present in an amount of 15 - 85 wt-%, preferably 20-80
wt-%, of the total weight of a)-d),
- glucan molecules of DP>10 are present in an amount of 15 - 85 wt-%, preferably 20-80
wt-%, further preferably 35 – 80 wt-%, of the total weight of a)-d),
- glucan molecules of DP>24 are present in an amount of 2 – 60 wt-%, preferably 4 – 58
wt-%, preferably 5 - 56 wt-% of the total weight of a)-d),
- glucan molecules of DP>25 are present in an amount of 1.9 – 59.5 wt-%, preferably 3.9
– 57.5 wt.-%, preferably 4.9 – 55.8 wt-% of the total weight of a)-d),
- glucan molecules of DP>30 are present in an amount of less than 59 wt-%, preferably
less than 55 wt-%, more preferably less than 50 wt-% of the total weight of a)-d),
- glucan molecules of DP > 55 are present in an amount of less than 15 wt-%, preferably
less than 12 wt-%, more preferably less than 10 wt-%, still more preferably less than 8
wt-% of the total weight of a)-d),
- glucan molecules of DP>111 are present in an amount of less than 1.5 wt-% of the total
weight of a)-d),
- glucan molecules of DP>246 are present in an amount of less than 0.6 wt-% of the total
weight of a)-d),
The weight average molecular weight of a)-d), taken together, may be Mw 0.8 - 15kD,
preferably Mw 1.0 – 10kD, more preferably Mw 1.2 – 6.2 kD or 1.0 - 6.2 kD, more preferably
1.4 – 6 kD, more preferably 1.6 to 5.8 kD,
The number average molecular weight of a)-d), taken together, may be Mn 0.2 - 3kD,
preferably Mn 0.3 – 3 kD, morepreferably Mn 0.5 - 3 kD or 0.7-3kD, more preferably 0.8 – 2.7
11742412_1 (GHMatters) P111977.NZ
kD, even more preferably 0.9 – 2.6 kD. Ranges of Mw and Mn can be combined in any
manner.
Hereinafter, embodiments concerning branching are described.
When %-values of branching are indicated, these values mean mol-%. The degree of
branching is defined herein as the percentage number of glucose monomers comprising a
branch (i.e. incorporated by three bonds within a glucan molecule) based on the total number
of all glucose monomers measured in a sample of the glucan of the invention with randomly
distributed molecular weights.
The degree of branching is measured by the method of standard methylation analysis or
alternatively by the method of reductive degradation after methylation. These methods may
be performed as described described in patent application WO 2007 128559 A2, but in the
present invention with glucans instead of fructans which were measured in WO 2007 128559
In one embodiment of this invention branching of the glucan starting material or final
preparation may be altered by parameters including the choice of the starting material, by
use of branching enzymes, and/or by incubation at chosen physico-chemical conditions
during, favoring aimed branching of the end-product.
Preferable physicochemical conditions include incubation at acidic or basic pH, a
temperature between 20 to 150°C, at pressures up to 10 bars, for variable times (between 1
minute and 100 hours, before, during, or after enzymatic treatment.
Branching enzyme include for example amylases, amyloguosidases, and transglucosidases.
Polyglucose chains in starch or dextrins are majorly formed by alpha 1,4 bounds. Branching
of starch or branching of of dextrins is defined of the percentage of alpha 1,6 bounds.
Dextran contains polyglucose chains majorly formed by alpha 1,6 bounds. Branching of
dextran is defined as the percentage of alpha 1,3 bonds.
In the frame of this invention, the term of branching shall be enlarged to any multiple nature
of bonds within a glucan preparation.
11742412_1 (GHMatters) P111977.NZ
The invention in particular relates to above preparations of soluble saccharide polymers,
which can be part of the composition of the invention, where saccharide polymers are
dextrins or dextrin derivatives, and preferably where dextrin branching by 1,6 glycosidic
bonds is higher than 11%, preferably higher than 12%, even more preferably higher than
13%, still more preferably higher than 15%, or higher than 17.5% or higher than 20%
The invention in particular relates to above preparations of soluble saccharide polymers,
which can be part of the composition of the invention, where saccharide polymers are
dextrins, where branching by 1,6 glycosidic bonds is lower than 7%, preferably lower than
6%, even more preferably lower than 5%, still more preferably lower than 4%, or lower than
3%, or lower than 2%, or lower than 1%, or lower than 0.1%.
The option of low or high branching to saccharide polymer compositions may be intended for
the following aim: Highly branched glucans degrade more slowly under the activity of
amylases, and therefore will degrade more slowly during peritoneal dialysis. Depending on
residual renal function of patients, one could adapt the polymer stability.
Less branched or unbranched unbranched saccharide polymers, for example in concentrated
(e.g. 3 to 6%) solutions, could be applied to patients with high residual renal function.
Increased degradation by degrading enzymes would increase possible uptake of small
molecular weight degradation products, keep ultrafiltration low and even allow some back
diffusion of liquid from the dialysate into the patients system. Small molecular weight
compounds such as maltose, iso-maltose, or the like would be excreted by the kidneys
before being transformed to glucose by intra-cellular maltases. As a result, sufficient ultra-
filtration would occur to guaranty low molecular weight products to enter the dialysate, but an
overall low ultra-filtration would sustain remaining residual renal function.
Low alpha 1-6 branching would further be advantageous for patients suspected for wheat
allergies.
Higher concentrated solutions (e.g. 5 to 7.5%), for example with highly branched
maltodextrins, could be applied to patients with low or no further residual renal function, to
increase UF rate and NUF, and to reduce enzymatic degradation, maintaining hyper-
osmolality for a longer time and reducing CHO uptake by the patient during the dialysis dwell.
11742412_1 (GHMatters) P111977.NZ
In one embodiment of the composition the glucan or glucan molecules are derivatized. A
definition of “derivatized” was given earlier.
Derivatization may be done by enzymatic, chemical and/or physical modification.
Glucan may be modified by etherification, esterification, alkylation, crosslinking, oxidation,
reduction, treatment with alkali and/or hydrolysis, particularly acidic or enzymatic hydrolysis.
Particularly one or more OH groups in the glucan may be modified in this way.
In a specific embodiment “derivatized” means that one or several OH groups in the glucan
are modified. The modification is particularly a substitution or functionalization of one or
several OH groups of the glucan. The modification may be a modification at one or more
terminal OH groups, OH groups at reducing ends and/or other OH groups.
The derivative may be a sugar-alcohol, particularly glucitol, a sugar-acid, particularly gluconic
acid, or an alkylglycoside.
In a specific embodiment, one or more OH groups may be modified to a group –O-R,
wherein R is selected from the group consisting of
i) a substituted or unsubstituted, branched or linear, saturated or unsaturated hydrocarbyl
group, particularly alkyl or hydroxyl alkyl, particularly selected from methyl ethyl, propyl (n-
or iso), butyl (n, iso or tert), hydroxyethyl, hydroxypropyl (n- or iso), hydroxybutyl (n, iso or
tert), CH(CH OH) , CH(CH (OH)) , CH(CH OH)(CHOHCH OH). This modification is
2 2 2 2 2 2
particularly applicable to a terminal or a reducing OH group, optionally also to other OH
groups,
ii) OH, -O-saccharide, -hydrocarbyloxy, substituted -hydrocarbyloxy, and -sulfoxy, CO-NH-
(CH2)n-COOH, -CO-NH-(CH2)n COO-, -CN, -Cl, -Br, -I, -NO , -(CH2)CN, -(CH2)n-Cl, -
(CH2)n-Br, -(CH2)n-I, -(CH2)n-NO2, -O-PO , -O-PO H-, -O-PO H , -NH , -NH-alkyl, -N(-
3 3 3 2 2
+ + + +
alkyl1,-alkyl2), -N H , -N H -alkyl, -N H(-alkyl1,-alkyl2),-N (-alkyl1,-alkyl2,-alkyl3), -B(OH) ,
3 2 2
-CHO, -CO-alkyl), -CF , -CN, -CH2CN, wherein alkyl may be a linear or branched (C1-C5)
alkyl, a partially unsaturated alkyl.
In another embodiment the present invention provides a solution of glucan starting material
or intermediate or final preparation in water, providing a solution of NaOCl, and adding the
NaOCl solution to the starch solution to oxidate the starch. Such oxidation may be leading to
transformation of the glucane to a gluconic acid.
11742412_1 (GHMatters) P111977.NZ
Another embodiment the invention provides dissolving of glucan starting material or
intermediate or final preparation in an acid and an alcohol. Such dissolution may occur for 1
to 40 hours. Such dissolution may be heated up to 100°, eventually up to higher temperature
up to 150°C under pressure. Such mixture under such conditions, may hydrolyze the starch
and alkylate it.
In another embodiment glucan starting material or intermediate or final preparation may be
submitted to ether synthesis, using alkylene-oxides such as methylene-, ethylene-,
propylene-, butylenes_oxide.
“Intermediate preparation” is particularly intended to mean a preparation of components b)-d)
of the composition, before a) is added, particularly when a) is not maltose.
The glucan in the invention may be free or substantially free of terminal formaldehyde, aldonic
acids, and/or furfurals.
In a further aspect, the present invention provides with a liquid aqueous composition,
comprising the composition of the invention and water. This liquid composition may be a
solution, a dispersion, an emulsion or a mixture of a solution, dispersion and/or or emulsion,
or a mixture of solution and dispersion, preferably a solution which means that the composition,
and other constituents, if present, is/are dissolved in the liquid phase. The liquid phase and
liquid composition may be predominantly (more than 90 vol-%, preferably more than 95 vol-%
of the liquid phase), or solely, water.
The liquid aqueous composition may be a dialysis fluid or used as a dialysis fluid, particularly
for peritoneal dialysis.
The liquid aqueous composition may have a ph of 6.8 to 7.7.
The liquid aqueous composition, particularly if it is a solution for dialysis, may also comprise
buffering agents (lactate, acetate, gluconate in particular) and other additives such as
aminoacids, insulin, polyols such as, for example, sorbitol, erythritol, mannitol, maltitol or
xylitol, or hydrogenated starch hydrolysates.
11742412_1 (GHMatters) P111977.NZ
In one embodiment, the liquid aqueous composition has an osmolality of 280 to 450
mosm/kg, preferred 290 to 420 mosm/kg.
In a further aspect of the invention, the composition as described above, or the liquid
aqueous composition as described above is intended for use as a medicament or medication
or for use in therapy.
More specifically, the composition as described above, or the composition as described
above, or the liquid aqueous composition as described above is intended for use as
- peritoneal therapeutic fluid or solution, particularly with reduced cytotoxicity
- dialysis fluid or solution, particularly peritoneal dialysis fluid or solution, particularly
with reduced cytotoxicity
- gastroenterological solution, such as digestive tract cleaning solutions,
- nutritional solution
- nutritional infusion,
- drug administration solution
- detoxifying solution
- physiological substitute or additive preparation, particularly for physiological body
fluids, more particularly as substitute or addition for blood, plasma, serum, or
interstitial body fluids
- adhesion reducing solution after surgery,
- solution for clyster,
- laxative,
- osmotic agent, particularly osmotic driver
- infant dietetic
- pharmaceutical agent with reduced cytotoxicity,
or in treatment of renal diseases.
The composition as described above, or the liquid aqueous composition as described above
may have a reduced cytotoxicity in comparison with products known so far. So, it may be
used for its own, or in one or more of mentioned applications, as agent with reduced
cytotoxicity.
Preferred medical solutions are solutions to replace or add to physiological body fluids, such
as blood, serum, and interstitial body fluids or solutions for gastroenterological application,
such as digestive tract cleaning solutions, clistiers, and nutritional solution. Solutions for
11742412_1 (GHMatters) P111977.NZ
intravenous, intraperitoneal, or other subcutaneous applications are also included. Preferred
medical solutions are peritoneal therapeutical solutions. Preferred peritoneal therapeutical
solutions are peritoneal dialysis solutions.
In the context of a medical application the solution may be applied to the human body, where
control of osmolality plays a role, either because physiological osmolality is intended or
because hypo- or hyper-osmolality is the aim.
A preferred medical application is the use of a composition of the invention, particularly a
bimodal composition, as an osmotic agent to adapt the medical solution to its specific aim.
Different medical solutions may have different osmotic pressures, for example for blood
substitutions the osmotic pressure of the medical solution may be near to physiological
concentration, whereas hyper-osmotic pressure may be applied for intestinal or peritoneal
applications.
In a further aspect, the composition of the invention is applied as osmotic agent to PTFs or
PDFs. In a further related aspect, a PTF, containing a claimed composition as osmotic agent,
is characterized by the application of a combination of two or more different of compositions
of the invention.
As to the use as osmotic driver, particularly in a PDF, mentioned compositions can be used to
generate a significantly higher NUF fluid volume than Icodextrin 7.5%, with a comparable or
higher Rate of NUF per CHO absorption, when applied as sole osmotic agent, at
concentrations less than 7.5%, preferably less than 7.2%, within a buffered solution of
physiological salt concentrations, for example in dwells of 2, 4 or 6 hours in peritoneal dialysis.
As stated above, compositions of the invention find use in different fields, including the
following:
- in infant dietetics, and feeding of medical patients;
- in the make-up of blood plasma substitutes;
- in the preparation of enteral and parenteral treatments;
- in the manufacturing of PTFs;
- and in the manufacture of dialysis solutions for the treatment of renal diseases.
The term “composition for medical application”, comprises any kind of physiologically
applicable solutions, such as gastroenterological solution, which may be drinkable, nutrient
11742412_1 (GHMatters) P111977.NZ
infusions and other drinkable applications, drug administration and detoxifying solutions,
physiological substitute preparations, or adhesion reducing solutions after surgery. A
preferred application of compositions for medical application in this invention are peritoneal
therapeutic fluids (PDF) or peritoneal dialysis fluids (PTF).
In a further aspect, the present invention provides a composition described hereinabove,
applied to the manufacturing of dialysis solutions.
In a further aspect, the present invention provides a peritoneal dialysis fluid comprising a
composition according to the invention.
In a further aspect, the invention provides a pharmaceutical composition including a PTF as
defined above.
In a further aspect, the present invention provides the use of described compositions to
generate a higher UF or NUF fluid volume than Extraneal® (icodextrin 7.5%), with a
comparable or higher rate of NUF (Volume) per CHO (weight) absorption, when applied as
sole osmolar agent at concentrations of less than 7.5%, within a buffered solution of
physiological salt concentrations, in peritoneal dialysis dwells of 6 hours or less.
Hereinafter, methods for obtaining products of the invention are described.
The glucan polymers in a composition of the present invention, particularly components b)-d)
(preferably in combination), or the composition if component a) is maltose, may be prepared
by acid and/or enzymatic hydrolysis of industrial saccharide solutions; enzymatic
repolymerisation and branching; followed by fractionation. Or they may be prepared by
ongoing fractionation, during such reactions, continuously separating reaction products out of
the mixture. Different intermediate preparations may be carried out separately and mixed
together later. Other low molecular weight molecules, such as a compound that is selected
from the group consisting of maltose, glycerol, an amino acid, an oligopeptide, or a mixture of
one or more thereof, may be added later, to obtain the aimed final composition. Industrial
saccharide solutions include starch syrups and maltose syrups. Industrial saccharides may
be pretreated for substitutions, partial substitutions or branching of their saccharide content,
or intermediate polysaccharide preparations may be treated to this aim.
11742412_1 (GHMatters) P111977.NZ
In still a further aspect, the invention is directed to a method for producing a liquid aqueous
composition as described above, comprising
- preparing an aqueous solution of starch, having a solids content of from 10 wt-% to
80 wt-%;
- gelatinization, by treating said solution successively with a specific combination of
enzymes chosen from amyloglucosidase and/or amylase,
- purifying the solution,
- fractionating the solution in such a way as to eliminate or decrease molecular-
weight saccharide fractions having a molecular weight higher than 40000 D, and to
recovering the other fractions,
- adding a compound that is selected from the group consisting of maltose, glycerol,
an amino acid, an oligopeptide, or a mixture of one or more thereof, preferably
maltose.
By fractionation and addition of a compound that is selected from the group consisting of
maltose, glycerol, an amino acid, an oligopeptide, or a mixture of one or more thereof,
maltose and/or glucose, a composition as defined above is obtained in the solution.
In a further step, glucose may be added. Glucose may be added separately or together with
a compound that is selected from the group consisting of maltose, glycerol, an amino acid,
an oligopeptide, or a mixture of one or more thereof. For example, when adding maltose, a
maltose product a can be added that comprises glucose. Maltose often comprises quantities
of glucose, for example when maltose syrup is added.
A dry composition of the invention can be obtained by drying the product of the
aforementioned process.
The initial ratio of amylase/amylopectin of specific starches may be exploited to simplify
generation of high or low branched maltodextrins, as required for specific applications.
Preferred soluble glucose polymers in the present invention are dextrins produced by
enzymatic treatment of starch.
Such soluble glucose polymers of the present invention are particularly prepared according
to a process comprising the combination of several or all of the following steps:
11742412_1 (GHMatters) P111977.NZ
1) choosing a starch of a defined amylopectin content, depending on the degree of branching
aimed for the maltodextrin or saccharide polymer preparation;
2) choosing or preparing an aqueous solution of starch, having a solids content of from 10%
to 80% by weight;
3) optionally treating said solutions with a branching enzyme, if a defined branching is aimed
4) optionally derivatizing,
) gelatinization, by treating said solution successively with a combination of enzymes
chosen from amyloglucosidase or amylase (e.g. 0.1% thermophilic amylase at pH 6 at 80 to
98°C), preferably for between 5 and 10 minutes;
6) optionally fractionating several solutions (e.g. one for high molecular weight of 4500 to
9000 D, one of molecular weight of 1500 to 18000 D and one for low molecular weight of 200
to 1500 D), to be further mixed, such a step allowing high flexibility, a large spectrum of
molecular weights of polymers in the final preparation, and at the same time, highest
stringency of selected polymers in the final medical application.
7) purifying the solution, for example by treatment on activated carbon, or by filtration (e.g.
glass pore filter, ceramic filters, or filter membranes), or by affinity procedures;
8) fractionating the solution in such a way as to eliminate or highly decrease high-molecular-
weight saccharide fractions, preferably those having a molecular weight higher than 40000
daltons, further preferably higher than 18 kD and to recover the other fractions;
9) choosing or preparing a maltose enriched powder or solution;
) optionally adapting low-molecular-weight fractions, preferably of 200 to 1500 D, to NUF
needs of the solution by addition of maltose, and optionally adding glucose, for example up
to 0.2% w/v% glucose total concentration of the final solution.
Above mentioned steps can also be used to further define steps that were mentioned
previously in a more general method.
When the solution is obtained by dissolving the polymers according to the invention in water,
it should be clear and colorless. It is preferably free of endotoxins, of peptidoglycans and of
beta-glucans, and also of contaminants originating from the starting material or from the
enzymatic preparations used to produce it.
To this effect, any highly branched polymers used in said solution will preferably have
undergone purification so as to remove any coloration or any unwanted contaminant such as
proteins, bacteria, bacterial toxins, viruses, fibers, traces of metals, etc. This purification step
can be carried out according to the techniques known to those skilled in the art.
11742412_1 (GHMatters) P111977.NZ
One step of the process in accordance with the invention may consist in collecting the
fractions of suitable molecular weight to generate sought glucose polymer preparation.
These fractions can be combined as they are, the polymers can be precipitated by adding
ethanol, purified and dried under vacuum or else by spray drying, or any technique known to
those skilled in the art.
In a further aspect the invention is directed to a container, for example PDF container, or kit
comprising at least one compartment, containing a liquid aqueous composition as described
above, for example as an osmotic agent, or a dry composition as described above. A
container or kit according to the invention may have a second compartment containing a
further part of the dialysis fluid, which, upon mixture with the acidic fluid from the first
compartment, reconstitutes a dialysis fluid with a pH between 7.0 and 7.5. Another
compartment of the container may comprise a buffer solution. The liquid aqueous
composition in the first compartment may have acidic pH, like to 1-6 or 2-4. The buffer
solution may have a pH suitable to produce the resulting pH the range of pH 6.5 to 8,
preferably of 6.8 to 7.7, more preferably of 7 to 7.5.
11742412_1 (GHMatters) P111977.NZ
EXAMPLES
In these Examples, the term “Extraneal” means a registered trade mark.
Example 1: Industrial saccharide polymer preparation:
A starch milk is prepared from an acid-fluidified, commercially available corn starch. A
suspension of starch containing 20 to 50 % solids is prepared by stirring, until complete
solubilization at 90°C. The solution is then cooled to 60° C and adjusted to pH between 6 and
6.5, by citric acid.
For gelatinization, a treatment with 0.1% heat-stable alpha-amylase of the starch is
carried out in the reaction medium, and the reaction is stopped by heating between 88 to 92
°C for 5 to 10 minutes.
For dextrinization the pH is adjusted to 4 to 5, the concentration of amylase is increased to
0.3% and the reaction is carried out for several further hours.
The final solution is fractionated in several steps on, including 30,000 10,000 5,000
dalton fractionation devices such as membrane or ceramic filters.
Table I shows two target glucan intermediate preparations or compositions of the
physicochemical characteristics of two PDF solutions in presence of physiological salt
conditions and pH 6.8 to 7.5, in accordance with the invention thus obtained.
11742412_1 (GHMatters) P111977.NZ
Table I:Intermediate scale PDF fluid production
PDF Sol. 1 Sol. 2
[CHO] (w/v) 5.0% 6.8%
total weight (g) in 2L 100 136
Osmolality (mOsm/kg) 290 to 350 320 to 340
Number average Mn (kD) 1.1 to 1.5 1.4 to 2.0
Weight average Mw (kD) 2.1 to 3.5 3.5 to 6.0
Poly-D 1.5 to 2.0 2.2 to 2.8
Osmolality (mOsm/kg) 300 to 320 320 to 340
Example 2: Experimental Preparation
In this example we generated polysaccharide preparations and final osmotically active
compositions of Mw between 3.4 and 6.1 kD and Mn between 2 and 3.7 kD.
In all cases such polymer fractions contained less than 1.5 wt-% of polymers with a
higher molecular weight than 18kD, and even less than 0.6 wt-% of polymers with a molecular
weight higher than 40 kD.
Starting material was Icodexrin from commercially available Extraneal®. Batches of 80 Liters
were submitted to 0.5m pelicon 2 ultracel® membranes as recommended by the supplier, at
3 to 4 L/m2 at entrance pressure of less than 2.5 Bar. Consecutive steps over membrane
cutoffs of 100kD, 30kD, 10kD, and 5kD were tested in different set-ups. Generally, every filter
step resulted in generation of about 5 to 10% of retentate, depending on the composition
concentration of the filtered solutions. Three intermediate saccharide polymer preparations
were generated this way, in the following called solutions 1, 2 and 3. All filtration steps were
carried out in the original Buffer of extraneal, and buffer composition as well as pH was
controlled throughout the workflow.
Solution 1 was generated from 80Liters of Extraneal going through Pelicon Ultracel® 100kD,
30kD, 10kD, 10kD and was finally concentrated on a 5kD Filter.
Solution 2 was generated running the same filter combination than for Solution 1, but in series,
so filtration on a following filter started, before the previous filtration cycle was finalized. This
save time but also reduced filtration efficacy.
11742412_1 (GHMatters) P111977.NZ
Solution 3 was generated as solution 2, but this time the 5kD membrane was applied twice as
a supplemental filter, before it was again applied to concentrate the intermediate saccharide
polymer preparation.
The results show that comparative results can be obtained by very different methods.
All solutions were analyzed on their carbohydrate composition by gel permeation
chromatography on a microsphere 60 SEC 5µm column of the dimensions of 300*4.6mm, at
1.2 ml/min at pressure between 5 and 200 bars. Chromatography was run with purified water.
Icodextrin, 70kD, 10kD and 5kD Dextran molecular weight markers were run in parallel to
identify the composition of the intermediate preparations. Carbohydrate concentration was
measured by RI Detection. In summary, total Carbohydrate concentration corresponded to the
area under the curve after background subtraction, following calibration established on
Icodextrin, maltose and glucose standard solutions. Quantification of molecular weight size
fractions was assessed using dextran molecular weight standards and Icodextrin as a
comparative standard.
Results of the molecular weight composition of the fractions are given in tables 2 to 5. “MW” in
the tables means “molecular weight”. “Mw” means “weight average molecular weight”.
11742412_1 (GHMatters) P111977.NZ
Table 2: Composition of Extraneal applied to experimental preparation of intermediate
saccharide polymer preparations: found Mw=14.1kD, Mn=5.8kD.
MW fractions Icodextrin wt mol
(KD) Refr.Index % Sum % number
90 509 0.10 0.00
60 11967 2.42 8.20 0.04
43 28061 5.67 0.13
51254 10.37 10.37 0.35
18 63270 12.80 0.71
12.5 54053 10.93 32.23 0.87
.5 42056 8.50 0.81
8.8 32712 6.62 0.75
7.5 26317 5.32 0.71
6.6 22325 4.51 0.68
.8 20131 4.07 0.70
19242 3.89 28.35 0.78
4.3 19485 3.94 0.92
3.9 22090 4.47 1.15
3.1 22263 4.50 1.45
2.6 15558 3.15 15.26 1.21
2.2 15558 3.15 1.43
1.8 8578 1.73 0.96
1.5 6453 1.30 4.01 0.87
1.2 4809 0.97 0.81
0.987 3618 0.73 0.74
0.827 2716 0.55 0.66
0.667 1098 0.22 0.33
0.5 366 0.07 1.58 0.15
11742412_1 (GHMatters) P111977.NZ
Table 3: Composition of Solution 1 (Mw=3.7kD, Mn=2.2kD)
MW fractions Sol. 1 wt mol
(KD) Refr.Index % Sum % number
90 71 0.07 0.00
60 171 0.16 0.46 0.00
43 258 0.24 0.01
434 0.40 0.40 0.01
18 787 0.73 0.04
12.5 1176 1.09 3.30 0.09
.5 1595 1.48 0.14
8.8 2066 1.92 0.22
7.5 2616 2.43 0.32
6.6 3260 3.03 0.46
.8 4080 3.79 0.65
5139 4.77 21.99 0.95
4.3 6525 6.06 1.41
3.9 8686 8.06 2.07
3.1 12950 12.02 3.88
2.6 13952 12.95 45.99 4.98
2.2 13952 12.95 5.89
1.8 6944 6.45 3.58
1.5 5705 5.30 16.38 3.53
1.2 4995 4.64 3.86
0.987 4686 4.35 4.41
0.827 4421 4.10 4.96
0.667 2386 2.22 3.32
0.5 858 0.80 11.47 1.59
11742412_1 (GHMatters) P111977.NZ
Table 4: Composition of solution 2: Mw=6kD, Mn=3.7kD
MW fractions Sol. 2 wt mol
(KD) Refr.Index % Sum % number
90 428 0.05 0.00
60 1116 0.12 0.44 0.00
43 2492 0.27 0.01
6595 0.72 0.72 0.02
18 18651 2.04 0.11
12.5 35458 3.88 11.73 0.31
.5 53111 5.81 0.55
8.8 67722 7.41 0.84
7.5 77730 8.51 1.13
6.6 83814 9.17 1.39
.8 88351 9.67 1.67
81734 8.94 51.68 1.79
4.3 72866 7.97 1.85
3.9 65137 7.13 1.83
3.1 57391 6.28 2.03
2.6 49303 5.40 24.20 2.08
2.2 49303 5.40 2.45
1.8 32714 3.58 1.99
1.5 24700 2.70 8.22 1.80
1.2 17689 1.94 1.61
0.987 12407 1.36 1.38
0.827 8942 0.98 1.18
0.667 4600 0.50 0.75
0.5 1498 0.16 3.00 0.33
11742412_1 (GHMatters) P111977.NZ
Table 5: Composition of solution 3: Mw 3.5 kD, Mn=2.1 kD
MW fractions Sol. 3 wt mol
(KD) Refr.Index % Sum % number
90 225 0.12 0.00
60 347 0.19 0.53 0.00
43 402 0.22 0.01
505 0.28 0.28 0.01
18 709 0.39 0.02
12.5 1031 0.56 1.79 0.04
.5 1540 0.84 0.08
8.8 2316 1.26 0.14
7.5 3474 1.89 0.25
6.6 5119 2.79 0.42
.8 7281 3.97 0.68
9923 5.41 22.34 1.08
4.3 12862 7.01 1.63
3.9 15763 8.60 2.20
3.1 18171 9.91 3.20
2.6 19631 10.71 39.92 4.12
2.2 19631 10.71 4.87
1.8 17506 9.55 5.30
1.5 14674 8.00 24.10 5.33
1.2 12016 6.55 5.46
0.987 10043 5.48 5.55
0.827 7375 4.02 4.86
0.667 2320 1.27 1.90
0.5 513 0.28 11.04 0.56
11742412_1 (GHMatters) P111977.NZ
Example 3: Examples for calculation of Mw and Mn for different osmotically active
compositions
Table 6: Calculation of Mw and Mn of solution 3 (on the example of 5.75% concentration of
saccharide polymer:
M(ni) MW(Mi)(kD) g/L(ni*Mi) g/L*MW(ni*Mi²)
0.001 90 0.07 6.3
0.002 0.11 6.5
0.003 43 0.13 5.4
0.005 30 0.16 4.7
0.012 18 0.22 4.0
0.026 12.5 0.32 4.0
0.046 10.5 0.48 5.1
0.083 8.8 0.73 6.4
0.145 7.5 1.09 8.2
0.243 6.6 1.61 10.6
0.394 5.8 2.28 13.2
0.622 5 3.11 15.6
0.938 4.3 4.03 17.3
1.267 3.9 4.94 19.3
1.838 3.1 5.70 17.7
2.368 2.6 6.16 16.0
2.798 2.2 6.16 13.5
3.050 1.8 5.49 9.9
3.067 1.5 4.60 6.9
3.140 1.2 3.77 4.5
3.191 0.987 3.15 3.1
2.796 0.827 2.31 1.9
1.091 0.667 0.73 0.5
0.322 0.5 0.16 0.1
Sums
27.447 57.50 200.8
For each fraction i, the concentration in Mol is taken as value for compound molecule number
(ni) of such a fraction, and the mean molecular weight of the fraction is accounted for as the
molecular weight Mi of all molecules of that fraction. Then we can establish the sums
∑(ni) = 27.5, ∑(ni*Mi) = 57.5, and ∑(ni*Mi²) = 200.8, and calculate
Mw = ∑(ni*Mi²)/∑(ni*Mi) = 3.49 kD, as well as
Mn = ∑(ni*Mi)/∑(ni) = 2.09 kD.
11742412_1 (GHMatters) P111977.NZ
Calculate Mw and Mn of maltose (1% solution):
M(ni) MW(Mi)(kDalton) g/L(ni*Mi) g/L*MW(ni*Mi²)
29 0.342 10 3.42
A fraction of 1% maltose corresponds to a single fraction of a concentration of 29M (ni), of a
molecular weight of 0.342 kD, resulting in ∑(ni)=ni=29, ∑(ni*Mi)=niMi=10, and
∑(ni*Mi²)=niMi²=3.42.
Calculate Mw and Mn of a composition of 5.75% saccharide polymers of sol 3 and 1 % maltose
= ∑(ni*Mi²)/∑(ni*Mi)
= [∑Sol3(ni*Mi²)+[∑mal(ni*Mi²)]/[∑Sol3 (ni*Mi)+ ∑mal (ni*Mi)]
= (200.8 + 3.42) / (57.5 + 10)
= 3.03
= Mn=∑(ni*Mi)/∑(ni)
= [∑Sol3(ni*Mi)+[∑mal(ni*Mi)]/[∑Sol3(ni)+ ∑mal(ni)]
= (57.5 + 10) / (27.4 + 29)
= 1.19
Table 7: Calculate Mw and Mn of a 1% amino acid mix
component M(ni) MW(Mi)(kDalton) g/L(ni*Mi) g/L*MW(ni*Mi²)
Adenine
0.77719 0.135 0.105 0.0142
L-Alanine
4.85591 0.089 0.432 0.0385
L-Arginine HCl
2.45793 0.174 0.428 0.0744
L-Asparagine
3.23999 0.132 0.428 0.0565
L-Aspartic Acid
3.21563 0.133 0.428 0.0569
L-Cysteine HCl
3.53454 0.121 0.428 0.0517
Glutamine
2.92931 0.146 0.428 0.0624
L-Glutamic Acid
2.90938 0.147 0.428 0.0629
Glycine
.70239 0.075 0.428 0.0321
L-Histidine HCl
2.75922 0.155 0.428 0.0663
Myo-Inositol
2.37600 0.18 0.428 0.0770
L-Isoleucine
3.26473 0.131 0.428 0.0560
L-Leucine
6.61336 0.131 0.866 0.1135
L-Lysine HCl
2.92931 0.146 0.428 0.0624
L-Methionine
2.87033 0.149 0.428 0.0637
Para-Aminobenzoic Acid
0.31363 0.137 0.043 0.0059
11742412_1 (GHMatters) P111977.NZ
L-Phenylalanine
2.59200 0.165 0.428 0.0706
L-Proline
3.71895 0.115 0.428 0.0492
L-Serine
4.07314 0.105 0.428 0.0449
L-Threonine
3.59394 0.119 0.428 0.0509
L-Tryptophan
2.09647 0.204 0.428 0.0872
L-Tyrosine
2.36287 0.181 0.428 0.0774
L-Valine
3.65538 0.117 0.428 0.0500
Uracil
3.81856 0.112 0.428 0.0479
76.66016 10.000 1.3725
For each fraction i, the concentration in Mol is taken as value for compound molecule number
(ni) of such a fraction, and the molecular weight of the corresponding amino acid is accounted
for as Mi. Then we can establish the sums
∑(ni) = 76.7, ∑(ni*Mi) = 10, and ∑(ni*Mi²) = 1.37, and calculate
Mw = ∑(ni*Mi²)/∑(ni*Mi) = 0.137 kD, as well as
Mn = ∑(ni*Mi)/∑(ni) = 0.130 kD.
Calculate Mw and Mn of a composition of 5.75% saccharide polymers of sol 3 and 1 % amino
acid mix
= ∑(ni*Mi²)/∑(ni*Mi)
= [∑Sol3(ni*Mi²)+[∑aam(ni*Mi²)]/[∑Sol3(ni*Mi)+ ∑aam(ni*Mi)]
= (200.8 + 1.4) / (57.5 + 10)
= 3.00
= Mn=∑(ni*Mi)/∑(ni)
= [∑Sol3(ni*Mi)+[∑aam(ni*Mi)]/[∑Sol3(ni)+ ∑aam(ni)]
= (57.5 + 10) / (27.4 + 76.7)
= 0.75
Example 4: Osmolality of claimed osmotically active compositions in physiological
buffer
Intermediate saccharide polymer preparations 1 and 3 from example 2 were measured for
osmolality at different concentrations in presence of 0, 1, 2 and 4 % maltose, using the freezing
point method, on an OSMOMAT 030 Gonotec Cryoscopic Osmometer. (results in mOsmol /
11742412_1 (GHMatters) P111977.NZ
kg). In all cases a higher osmolality as compared to Icodextrin was found.
Experimental results:
All intermediate preparations, preparations and solutions of such preparations were
continuously kept in 1xBuffer (5.4g/l NaCl, 4.5 g/l Na-lactate, 0.257 g/l CaCl , and 0.051 g/l
MgCl , at pH5.5. Maltose was added to intermediate saccharide polymer preparations at
different concentrations. Therefore, variations in osmolality are solely due to variation of
concentration of intermediate saccharide polymer preparations tables (8 to 11).
Intermediate polymer preparation w/o maltose Intmediate Polymer preparation + 1% Maltose
intermediate prep intermediate prep
% total CHO % Sol 1 Sol 3 ICO % total CHO % Sol 1 Sol 3 ICO
7.50% 7.50% 284 8.50% 7.50% 315
6.80% 6.75% 311 7.80% 6.80% 343
.75% 5.75% 308 303 6.75% 5.75% 334 329
4.80% 4.80% 305 298 5.80% 4.80% 331 327
3.90% 3.90% 303 295 4.90% 3.90% 330 326
3% 3% 295 293 4% 3% 326 322
Table 8: Compositions w/o Maltose Addition Table 9: Compositions with 1% Maltose
Intmediate Polymer preparation + 2% Maltose Intmediate Polymer preparation + 4% Maltose
intermediate prep intermediate prep
% total CHO % Sol 1 Sol 3 ICO % total CHO % Sol 1 Sol 3 ICO
9.50% 7.50% 350 11.50% 7.50% 409
8.80% 6.80% 373 10.80% 6.80% 433
7.75% 5.75% 373 363 9.75% 5.75% 431 416
6.80% 4.80% 366 359 8.80% 4.80% 427 417
.90% 3.90% 361 356 7.90% 3.90% 418 415
% 3% 360 355 7% 3% 417 410
Table 10: Compositions with 2% Maltose Table 11: Compositions with 4% Maltose
Obtained experimental results were normalized and extrapolated to estimate osmolalilties for
the three solutions over the range of concentrations claimed by this application (tables 12-15).
Normalized and extrapolated osmolalities for solutions of this invention
11742412_1 (GHMatters) P111977.NZ
Interm. polymer prep w/o maltose Interm. polymer prep with 1% maltose
0% maltose intermediate prep 1% maltose intermediate prep
% total CHO % Sol 1 Sol 3 % total CHO % Sol 1 Sol 3
6.80% 6.80% 311-312 306-308 6.75% 5.75% 335-337 330-332
.75% 5.75% 307-309 302-304 5.80% 4.80% 332-334 327-329
4.80% 4.80% 304-305 298-299 4.90% 3.90% 328-330 323-325
3.90% 3.90% 301-303 294-296 4% 3% 325-327 320-322
3% 3% 295-297 292-293 3% 2% 321-323 316-318
2% 2% 292-294 287-289 2% 1% 318-320 313-315
Table 12: Compositions w/o Maltose Addition Table 13: Compositions with 1% Maltose
Intm. Polymer prep + 2% Maltose
2% maltose intermediate prep
Intm. Polymer prep + 4% Maltose
% total CHO % Sol 1 Sol 3
6.80% 4.80% 366-368 359-361 4% maltose intermediate prep
.90% 3.90% 362-364 356-358
% total CHO % Sol 1 Sol 3
% 3% 359-361 352-354
7% 3% 418-420 409-411
4% 2% 356-358 349-351 6% 2% 415-417 406-408
3% 1% 352-354 346-348 5% 1% 412-414 402-404
Table 14: Compositions with 2% Maltose Table 15: Compositions with 4% Maltose
Those skilled in the art understand that other solutions may be prepared with intermediate
saccharide polymer preparations of lower Mw, Mn, than solutions 1 and 3. Such solutions
would show higher osmolalities at comparable concentrations up to 500 mOsmol / kg, in
presence of 4% maltose.
We also measured osmolalities of Solution 3 saccharide polymers 5.75% and Icodextrin 7.5%,
both in physiological buffer, adding 1% of an amino acid mix (composition see example3),
maltose, sucrose, glucose, glycerol, carnitine, or carnisol (Table 16).
Table 16: Osmolalities of other small molecular weight osmotic drivers in comparison to
maltose (at 1%) added to solution 3 (5.75ù or Icodextrin 7.5%):
no add 1% aam 1% mal 1% suc 1% glu 1% gly 1% carni 1% carno
Sol3 glucans (5.15%) 308 382 340 341 366 410 396 357 mOsm/L
Icodextrin (7.5 %) 284 354 305 301 328 402 367 318-348 mOsm/L
Example 5: assessing Ultrafiltration and CHO absorption in an animal model
Peritoneal dialysis dwell times vary from less than 2 hours, for example in automated peritoneal
dialysis (ADP); over 4 to 6 hours, for example in continuous ambulatory peritoneal dialysis
(CAPD); to 8 to 12 hours in long dialysis dwells, for example whole day or whole night dwells.
11742412_1 (GHMatters) P111977.NZ
In this application, dwells of up to 6 hours are referred to as short PD dwells, whereas dwells
of 8 hours and longer are referred to as long dwells.
One of our saccharide polymer preparations (Solution 3, at 5.75 wt-% glucan) was
supplemented with 1% maltose to give solution 4 (example 3, Mw=3.03 kD, Mn=1.19kD) at a
total CHO concentration of 6.75%M, and an osmolality of 329 mOsmol/kg, and was applied to
the rabbit model described by Leypoldt et al. (2013, PDI Vol. 33, pp 124-131), in comparison
to commercial Extraneal® containing 7.5% Icodextrin. 6 rabbits were separated into two
groups A and B. The two solutions were tested on both groups in the frame of a cross over
study.
Leypoldt et al. had been calculating ultrafiltration after a single dwell of 240 minutes, correcting
for resting volume with a fluorescent volume marker. Instead, we carried out 5 dwells a day at
3, 30, 60, 120 and 240 minutes. The 3 minutes dwell served as a pre-flushing dwell to occupy
volume that cannot be recovered from the peritoneum in a single dwell, and to guaranty that
only fresh PD fluid is present in the peritoneum for the 30 minutes dwell. Further dwells were
run consecutively through the day. At the end of each dwell, dialysate was recovered, and
weighted to establish dialysate volume and to calculate net ultrafiltration volume. Samples of
every dialysate were submitted to measure total CHO concentrations. Methods for CHO
quantification as described in example 2. Altogether 6 rabbits were submitted to dialysis
comparing an experimental dialysis solution corresponding to this invention with Icodextrin. 3
rabbits started with the test solution, the other 3 rabbits started with the Icodextrin control
solution. After 2 days dialysis, rabbits were let to recover for two days, before being switched
to the other dialysis solution respectively. All together 96 dialysis dwells were run, 16 dwells
on each rabbit. We did not observe difference of dwell volumes depending on which solution
a rabbit started on. For statistical evaluation we applied a single sided t-test with independent
variances for both tested groups. Every dwell was regarded as an independent event and no
correction for multiple testing was carried out. Table 17 shows results on net ultrafiltration
volumes (in ml) for each dwell. (* statistically significance at < 5%).
11742412_1 (GHMatters) P111977.NZ
NUF (ml) NUF (ml) pval
Test Sol.4 Icodextrin
30 min 9 (±18) -2 (±6) 0.063
60 min 34 (±13) 12 (±8) 0.001*
120 min 46 (±13) 13 (±14) 0.002*
240 min 50 (±8) 28 (±21) 0.011*
Table 17: NUF comparisons at different dwell times.
Average CHO absorptions and NUF/CHOabs ratios are calculated in table 18
NUF(ml) NUF (ml) CHOabs. CHOabs. NUF/CHO NUF/CHO
Test sol.4 Ico Test (g) Ico (g) Test Ico
30 min 9 -2 3.88 3.69 2.4 -0.5
60 min 34 12 4.18 3.58 8.1 3.3
120 min 46 13 5.15 4.78 9.0 2.7
240 min 50 28 5.85 4.75 8.6 5.9
Table 18: Average CHO absorption and calculation of NUF/CHO ratios, comparing 2 Solutions
at different dwell times.
In summary, we found:
- an average NUF of 9.3ml/120ml for a solution on the basis of this invention, after a 30 minutes
dwell, versus -2 ml/120ml for Extraneal.
- an average NUF of 34ml/120ml for our composition after a 60 minutes dwell, versus
12.3ml/120ml for Extraneal.
- an average NUF of 46ml/120ml for our composition after a 120 minutes dwell, versus
13ml/120ml for Extraneal.
- an average NUF of 50ml/120ml for our composition after a 240 minutes dwell, versus
28ml/120ml for Extraneal.
These results were very surprising to us. Based on data reported by Leypoldt et al. we would
have expected NUF values around 50ml/120ml for Extraneal at 20 min. Most likely minor
differences in realization of the model, the fact that we worked with 4 real dwells through the
day, instead of a single dwell, and that we only considered the volume recovered from the
11742412_1 (GHMatters) P111977.NZ
rabbits, without corrections for resting volumes after the dwell, accounts for this difference. On
the other hand resting volumes should be less of an issue in our study since we did multiple
dwells during a day. Nevertheless, the comparatively higher performance of our composition
versus Icodextrin at all time points, but more drastical at time points 60, 120 and 240 of this
model, corresponding to short dwells in humans, by far exceeded our expectations. The model
indicates that our compositions, even at lower concentrations then those applied in this animal
experiment, would be highly efficient osmotic drivers for any medical application in general and
for peritoneal dialysis specifically.
Furthermore, the ration NUF/ CHO abs. is higher for the test solution at every time point. More
importantly the three best values for this ration are all for the test solution, event at 240 min,
which had previously been characterized to correspond to a long dwell.
11742412_1 (GHMatters) P111977.NZ
Claims (1)
1. A composition, comprising: a) a compound that is selected from the group consisting of maltose, glycerol, an amino acid, an oligopeptide, or a mixture of one or more thereof, in a content of 5 to 75 wt-% of the total weight of a)-d), b) glucose in a content of less than
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164425.5A EP3381484A1 (en) | 2017-03-31 | 2017-03-31 | Carbohydrate composition for dialysis |
EP17164425.5 | 2017-03-31 | ||
PCT/EP2018/057275 WO2018146345A1 (en) | 2017-03-31 | 2018-03-22 | Carbohydrate composition for dialysis |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ757717A NZ757717A (en) | 2020-12-18 |
NZ757717B2 true NZ757717B2 (en) | 2021-03-19 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7411268B2 (en) | Carbohydrate composition for dialysis | |
AU689857B2 (en) | Peritoneal dialysis solutions containing maltodextrins and amino acids | |
CN1163236C (en) | Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis | |
ES2626831T3 (en) | Highly branched soluble glucose polymers for enteral, parenteral and peritoneal dialysis nutrition | |
CA2510788A1 (en) | Biocompatible dialysis fluids containing icodextrins | |
JP2010209349A (en) | Highly branched, unsubstituted or low-substituted starch product, dialysis solution and plasma expander containing the same, and use thereof | |
JP2013518562A (en) | Branched soluble glucose polymer for peritoneal dialysis | |
JP2017114886A (en) | Peritoneal dialysis solution comprising glucose polymer | |
KR840001798B1 (en) | Method for the controlled release administration | |
NZ757717B2 (en) | Carbohydrate composition for dialysis | |
CN107375318A (en) | Chitosan oligosaccharide peritoneal dialysis solution | |
CN111732675A (en) | Hyaluronic acid-glucosamine graft copolymer, preparation method and application thereof | |
JP2004016615A (en) | Peritoneal dialysis liquid containing crystalloid osmotic agent and colloidal osmotic agent |